Clinical Trials Logo

Clinical Trial Summary

The name of this prospective study is a multicenter, open-label, randomized controlled clinical study of the efficacy and safety of Ondansetron Oral Soluble Pellicles for the prevention of delayed nausea and vomiting induced by highly emetogenic chemotherapy.


Clinical Trial Description

The aim of this study is to observe the efficacy and safety of ondansetron in delayed nausea and vomiting by its continuous dosing, and it is planned to enroll 184 first-time recipients of highly emetogenic single-day chemotherapy regimens (cisplatin dose 60-75 mg/m2; anthracycline compounds adriamycin ≥ 60 mg/m2 or epothilone ≥ 90 mg/m2 ) who were initiated on a triple combination regimen of fosaprepitant + ondansetron orally soluble film + dexamethasone triple regimen for nausea and vomiting prophylaxis in patients. The primary observation was the incidence and severity of delayed nausea and vomiting in both groups from day 5 after chemotherapy to the second cycle of chemotherapy. The secondary observation indexes include the incidence and severity of delayed nausea in patients in both groups from day 5 after chemotherapy to before the second cycle of chemotherapy; the incidence and severity of anticipatory nausea/vomiting in the second cycle of chemotherapy in both groups; the incidence and severity of nausea/vomiting in patients in both groups on days 1-4 after chemotherapy; and the incidence of adverse events and serious adverse reactions, with a focus on the antiemetic drugs common constipation, headache and other events. This trial was randomized into groups, and the experimental group was preset as group A and the control group as group B. The prevention of nausea and vomiting was carried out with the triple regimen of fosaprepitant (Tanneng, Jiangsu Hausen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone prior to chemotherapy, and the patients were divided into the treatment group A and the control group B by the use of Ondansetron Oral Soluble Pellicles for continuation of the prophylaxis on the 5-7 days after the chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06282211
Study type Interventional
Source The First Affiliated Hospital of Xinxiang Medical College
Contact Yinghua Ji
Phone 13663030446
Email 54234317@qq.com
Status Recruiting
Phase Phase 3
Start date February 20, 2024
Completion date December 29, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05016180 - Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery Phase 2
Withdrawn NCT00891761 - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Phase 3
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT05533281 - Efficacy of Three Antiemetics in Preventing Nausea and Vomiting Phase 4
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Completed NCT00293384 - Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant N/A
Completed NCT00006348 - Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Phase 3
Completed NCT00003817 - Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy Phase 2
Completed NCT00004895 - Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Phase 2
Active, not recruiting NCT06045364 - Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation Phase 1/Phase 2
Completed NCT00978185 - Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy Phase 3
Completed NCT00064272 - UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer Phase 2
Completed NCT00003213 - Drugs to Reduce the Side Effects of Chemotherapy Phase 3
Recruiting NCT05690802 - The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV N/A
Recruiting NCT06314906 - Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer Phase 3
Completed NCT00590317 - Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department Phase 2
Completed NCT03185156 - The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate Phase 4
Not yet recruiting NCT06382012 - Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Phase 2/Phase 3
Terminated NCT01275664 - Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer N/A
Completed NCT01590147 - Supportive Intervention Programs Study N/A